抗凝期间(活化)血管性血友病因子水平升高与静脉血栓栓塞症早期复发相关
基于VISTA随机对照试验(2011-2015)的629例首次无诱因静脉血栓栓塞症(VTE)患者,在停用维生素K拮抗剂前后检测血管性血友病因子(VWF)、活化VWF(aVWF)等标志物,随访2年。VWF与aVWF每升高10单位与复发风险增加相关,关联在早期复发(<3个月)及男性中更强,晚期复发未见关联。
要点
- VWF每升高10单位,复发风险HR 1.03(95%CI 1.01-1.06);aVWF HR 1.02(95%CI 1.00-1.05)。
- VWF与aVWF与早期复发(<3个月)关联更强,与晚期复发(>3个月)无关联。
- 分层显示VWF与aVWF在男性中与复发风险增加相关,在女性中无关联。
核心结论
- 抗凝期间VWF与aVWF水平升高与男性早期复发相关,可能作为预测VTE复发的生物标志物。
研究设计与样本
- 基于VISTA随机对照试验(2011-2015)的前瞻性分析,纳入629例首次无诱因VTE、接受维生素K拮抗剂治疗6个月后停药的患者,停药后随访2年评估复发,并在抗凝停止前后检测血浆标志物,采用Cox回归分析标志物与复发的关联。
主要发现
- 629例患者中75例(12%)复发,其中11例(15%)在1个月内、29例(39%)在3个月内、46例(61%)在3个月后。
- VWF每升高10单位与复发风险增加相关(HR 1.03;95%CI 1.01-1.06),aVWF每升高10单位亦相关(HR 1.02;95%CI 1.00-1.05)。
- VWF与aVWF与早期复发(<3个月)关联更强,而与晚期复发(>3个月)无关联。
- 分层分析显示VWF与aVWF在男性中与复发风险增加相关,在女性中无关联。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) can recur shortly after stopping anticoagulation, highlighting the need for reliable biomarkers to identify high-risk patients during treatment. OBJECTIVES: To determine whether platelet and endothelial markers predict VTE recurrence. METHODS: We used data and samples from the randomized controlled VISTA trial (2011-2015), which included patients with unprovoked VTE who were treated with vitamin K antagonists for 6 months. After treatment cessation, patients were followed for 2 years to assess recurrence. This dataset formed the basis for the current prospective analysis, in which plasma levels of von Willebrand factor (VWF), active VWF (aVWF), soluble P-selectin, soluble thrombomodulin, CXCL4, and CXCL7 were measured before and after cessation of anticoagulation. Associations between biomarker levels and recurrence were analyzed using Cox regression. RESULTS: Plasma samples from 629 patients with a first unprovoked VTE who discontinued vitamin K antagonists were analyzed. Recurrence occurred in 75 patients (12%); 11 (15%) within 1 month, 29 (39%) within 3 months, and 46 (61%) after 3 months. Elevated levels of VWF and aVWF were associated with an increased risk of recurrence per 10-unit increase (VWF: hazard ratio, 1.03; 95% CI, 1.01-1.06; aVWF: hazard ratio, 1.02; 95% CI, 1.00-1.05). Associations were stronger for early recurrence (<3 months), while (a)VWF levels were not associated with late recurrence (>3 months). Stratification showed that VWF and aVWF were associated with increased recurrence risk in men, but not in women. CONCLUSION: Elevated levels of VWF and aVWF during anticoagulation were associated with early recurrence in men and might serve as biomarkers for predicting VTE recurrence.
引用
- Poolen GC, Urbanus RT, Roest M, et al. Elevated levels of (active) von Willebrand factor during anticoagulation are associated with early recurrence of venous thromboembolism. J Thromb Haemost. 2025. PMID: 40374116. doi:10.1016/j.jtha.2025.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。